How a Legal Backlash Against Big Tech Is Forcing Big Changes
A series of lawsuits has created a new de facto regulatory regime as courts order companies like Meta and Google to change their business practices — and pay up.
Read moreLunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
Sep 22, 2026
New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets. Positioned for $400M to $1.2 Billion US Countermeasures Program with AI Platform to Meet Battlefield and Terrorism Threats. $LNAI Names Six Broker-Dealers in Expanded Naked Short Selling Suit
SACRAMENTO, Calif. - Sept. 22, 2026 - PRLog -- Lunai Bioworks, Inc. (N A S D A Q: LNAI) $LNAI is continuing to build an increasingly sophisticated platform at the intersection of artificial intelligence, precision medicine, neuroscience and biodefense — and its latest Parkinson's development could become one of the company's most important pieces of the story.
Lunai has announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc., adding human cellular phenotyping capabilities to its growing Parkinson's disease discovery and validation platform.
The agreement is significant because it addresses a critical question facing AI-driven drug discovery: Can computationally identified patient subtypes and disease signals be reproduced in actual human biology?
Through its wholly owned BioSymetrics subsidiary and its Augusta AI platform, Lunai has already identified three clinically distinct Parkinson's patient subtypes from longitudinal clinical and proteomic data. The new Tanaist collaboration is designed to take that work another step — connecting those patient-defined subtypes to measurable differences in human cellular biology.
That could create a more complete development pathway:
Patient Stratification → Biological Validation → Biomarkers → Therapeutic Targets
Tanaist Adds a New Biological Lens
Under the agreement, Lunai receives exclusive rights to Tanaist's licensed cellular phenotyping technology within the Parkinson's disease field for programs based on Lunai's patient phenoclusters.
The companies plan to evaluate whether Lunai's clinical and proteomic signatures can be reproduced across additional Parkinson's cohorts and whether those signatures correspond to distinct cellular phenotypes.
That is an important distinction.
Rather than stopping with an AI-generated classification, Lunai is seeking to determine whether those classifications have underlying biological meaning.
Tanaist's precision-medicine platform combines patient data with dynamic human cellular phenotyping. According to the companies, the scientific approach supporting the platform has been described in peer-reviewed research published in Nature Genetics and Science Translational Medicine, including research connecting human cellular phenotypes with genetic mechanisms, disease biology and potential therapeutic targets.
For Lunai, that creates another independent validation layer around its Parkinson's program.
Three Parkinson's Subtypes Become the Foundation
Lunai previously analyzed longitudinal clinical information and more than 4,500 proteomic probes from more than 650 participants in the Parkinson's Progression Markers Initiative (PPMI).
The Augusta AI analysis identified three clinically distinct Parkinson's subtypes associated with different disease-progression patterns.
The groups were characterized by:
The analysis connected baseline clinical and proteomic characteristics with subsequent disease progression over a median follow-up of approximately 2.5 years, with many participants followed for more than five years.
The next question is arguably even more important: Do these differences correspond to different underlying biology?
The Tanaist agreement is designed to help answer that question.
If the patient subtypes can be reproduced across independent cohorts and connected to measurable cellular mechanisms, the findings could potentially become more useful for patient enrichment, biomarker development and therapeutic-target selection.
LNAI Is Building Multiple Validation Paths
The Tanaist agreement also complements Lunai's previously announced collaboration with BrainStorm Therapeutics.
In August, Lunai announced a definitive Master Collaboration Agreement with BrainStorm focused on Parkinson's disease, with an initial data readout targeted for the first half of 2027.
That collaboration combines Lunai's AI-based patient stratification and biomarker capabilities with BrainStorm's patient-derived human midbrain organoid technology.
Together, the BrainStorm and Tanaist relationships give Lunai multiple experimental approaches for testing its computational findings.
The strategic objective is becoming clearer: Lunai is not simply attempting to use AI to identify patterns in Parkinson's disease. It is building a framework designed to determine which AI-derived signals are reproducible, biologically meaningful and potentially actionable for therapeutic development.
From AI Discovery Toward Therapeutic Application
This is where the newest agreement could become particularly interesting to investors.
AI can identify patterns across enormous datasets that may be difficult to recognize using traditional approaches. But pharmaceutical development ultimately requires biological validation.
Lunai's stated strategy is therefore moving toward a more integrated model in which:
AI identifies patient subtypes → human biology tests those hypotheses → biomarkers help identify relevant patients → therapeutic targets can be prioritized.
Dr. Gabe Musso, Chief Scientific Officer at BioSymetrics, described the Tanaist collaboration as an important step in moving Lunai's Parkinson's findings from computational discovery toward therapeutic application.
The company says Lunai will own collaboration-generated analyses, biomarker findings and other results as provided under the agreement, while Tanaist retains ownership of its underlying platform.
Parkinson's Is Only One Part of the LNAI Story
While the Parkinson's platform is rapidly becoming a major component of the investment narrative, Lunai's broader strategy remains diversified.
On September 16, 2026, BioSymetrics reported results from a technical case study evaluating AI-based screening for potential acetylcholinesterase (AChE) inhibition. Using NIH Tox21 data covering 9,667 compounds, Lunai reported an AUROC of 0.88, along with 33% precision at 70% recall and approximately 5.1-fold enrichment versus the dataset's reported 6.4% prevalence of AChE-active entries.
The company positioned the structure-based system as a potential downstream screening layer for molecules generated by AI systems, while emphasizing that the work is a technical case study and not evidence of clinical neurotoxicity prevention or a comprehensive chemical-threat detection system.
Lunai has also been pursuing biodefense applications and a revenue-generating defense collaboration, giving the company potential applications beyond conventional pharmaceutical discovery.
Key Catalysts Investors Will Be Watching
The rapidly expanding platform gives LNAI several areas to watch as the company moves forward:
Lunai has also been dealing with corporate and capital-markets issues, including litigation involving alleged naked short selling. In August, the company announced that its Second Amended Complaint named six registered broker-dealers and two broker-dealer principals as defendants. Those allegations remain subject to the judicial process. A September 4 company correction stated that it changed only the reference link to the complaint and did not alter the substantive content of the earlier release.
An Increasingly Interesting AI-Biotech Convergence Story
The latest Tanaist agreement potentially adds an important missing piece to the Lunai Bioworks story.
The company already has the AI, the patient data, the proteomic analysis and the identified Parkinson's subtypes. Now it is adding another avenue for determining whether those computational discoveries correspond to real, measurable human cellular biology.
That evolution could be important.
The potential value of AI-driven drug discovery ultimately depends not simply on finding patterns, but on determining which patterns can withstand independent validation and translate into meaningful biological and therapeutic hypotheses.
Lunai is attempting to build exactly that bridge.
With Tanaist providing human cellular phenotyping, BrainStorm providing complementary experimental validation, BioSymetrics providing AI-powered patient stratification, and the company continuing its chemical-risk and biodefense work, LNAI is developing a platform that spans several rapidly advancing areas of biotechnology.
The combination of AI-driven precision medicine, human biological validation, Parkinson's disease research, biodefense and chemical-risk screening gives Lunai Bioworks $LNAI multifaceted story for investors to follow.
For more information on LNAI visit: www.lunaibioworks.com
--------------------------------------------------------------------------------------------------------------
Media Contact
Company Name: Lunai Bioworks (N A S D A Q: LNAI)
Contact: Aysha Rashid
Email: [email protected] or [email protected]
Phone: (424) 222-9301
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement | More news from this source
Press release distribution by PRLog
SACRAMENTO, Calif. - Sept. 22, 2026 - PRLog -- Lunai Bioworks, Inc. (N A S D A Q: LNAI) $LNAI is continuing to build an increasingly sophisticated platform at the intersection of artificial intelligence, precision medicine, neuroscience and biodefense — and its latest Parkinson's development could become one of the company's most important pieces of the story.
Lunai has announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc., adding human cellular phenotyping capabilities to its growing Parkinson's disease discovery and validation platform.
The agreement is significant because it addresses a critical question facing AI-driven drug discovery: Can computationally identified patient subtypes and disease signals be reproduced in actual human biology?
Through its wholly owned BioSymetrics subsidiary and its Augusta AI platform, Lunai has already identified three clinically distinct Parkinson's patient subtypes from longitudinal clinical and proteomic data. The new Tanaist collaboration is designed to take that work another step — connecting those patient-defined subtypes to measurable differences in human cellular biology.
That could create a more complete development pathway:
Patient Stratification → Biological Validation → Biomarkers → Therapeutic Targets
Tanaist Adds a New Biological Lens
Under the agreement, Lunai receives exclusive rights to Tanaist's licensed cellular phenotyping technology within the Parkinson's disease field for programs based on Lunai's patient phenoclusters.
The companies plan to evaluate whether Lunai's clinical and proteomic signatures can be reproduced across additional Parkinson's cohorts and whether those signatures correspond to distinct cellular phenotypes.
That is an important distinction.
Rather than stopping with an AI-generated classification, Lunai is seeking to determine whether those classifications have underlying biological meaning.
Tanaist's precision-medicine platform combines patient data with dynamic human cellular phenotyping. According to the companies, the scientific approach supporting the platform has been described in peer-reviewed research published in Nature Genetics and Science Translational Medicine, including research connecting human cellular phenotypes with genetic mechanisms, disease biology and potential therapeutic targets.
For Lunai, that creates another independent validation layer around its Parkinson's program.
Three Parkinson's Subtypes Become the Foundation
Lunai previously analyzed longitudinal clinical information and more than 4,500 proteomic probes from more than 650 participants in the Parkinson's Progression Markers Initiative (PPMI).
The Augusta AI analysis identified three clinically distinct Parkinson's subtypes associated with different disease-progression patterns.
The groups were characterized by:
- Fast motor progression
- Rapid neurological and cognitive decline
- Female-enriched functional impairment
The analysis connected baseline clinical and proteomic characteristics with subsequent disease progression over a median follow-up of approximately 2.5 years, with many participants followed for more than five years.
The next question is arguably even more important: Do these differences correspond to different underlying biology?
The Tanaist agreement is designed to help answer that question.
If the patient subtypes can be reproduced across independent cohorts and connected to measurable cellular mechanisms, the findings could potentially become more useful for patient enrichment, biomarker development and therapeutic-target selection.
LNAI Is Building Multiple Validation Paths
The Tanaist agreement also complements Lunai's previously announced collaboration with BrainStorm Therapeutics.
In August, Lunai announced a definitive Master Collaboration Agreement with BrainStorm focused on Parkinson's disease, with an initial data readout targeted for the first half of 2027.
That collaboration combines Lunai's AI-based patient stratification and biomarker capabilities with BrainStorm's patient-derived human midbrain organoid technology.
Together, the BrainStorm and Tanaist relationships give Lunai multiple experimental approaches for testing its computational findings.
The strategic objective is becoming clearer: Lunai is not simply attempting to use AI to identify patterns in Parkinson's disease. It is building a framework designed to determine which AI-derived signals are reproducible, biologically meaningful and potentially actionable for therapeutic development.
From AI Discovery Toward Therapeutic Application
This is where the newest agreement could become particularly interesting to investors.
AI can identify patterns across enormous datasets that may be difficult to recognize using traditional approaches. But pharmaceutical development ultimately requires biological validation.
Lunai's stated strategy is therefore moving toward a more integrated model in which:
AI identifies patient subtypes → human biology tests those hypotheses → biomarkers help identify relevant patients → therapeutic targets can be prioritized.
Dr. Gabe Musso, Chief Scientific Officer at BioSymetrics, described the Tanaist collaboration as an important step in moving Lunai's Parkinson's findings from computational discovery toward therapeutic application.
The company says Lunai will own collaboration-generated analyses, biomarker findings and other results as provided under the agreement, while Tanaist retains ownership of its underlying platform.
Parkinson's Is Only One Part of the LNAI Story
While the Parkinson's platform is rapidly becoming a major component of the investment narrative, Lunai's broader strategy remains diversified.
On September 16, 2026, BioSymetrics reported results from a technical case study evaluating AI-based screening for potential acetylcholinesterase (AChE) inhibition. Using NIH Tox21 data covering 9,667 compounds, Lunai reported an AUROC of 0.88, along with 33% precision at 70% recall and approximately 5.1-fold enrichment versus the dataset's reported 6.4% prevalence of AChE-active entries.
The company positioned the structure-based system as a potential downstream screening layer for molecules generated by AI systems, while emphasizing that the work is a technical case study and not evidence of clinical neurotoxicity prevention or a comprehensive chemical-threat detection system.
Lunai has also been pursuing biodefense applications and a revenue-generating defense collaboration, giving the company potential applications beyond conventional pharmaceutical discovery.
Key Catalysts Investors Will Be Watching
The rapidly expanding platform gives LNAI several areas to watch as the company moves forward:
- Tanaist Parkinson's validation work and additional cohort analysis
- BrainStorm collaboration and targeted first-half 2027 data
- Validation of Lunai's three Parkinson's patient subtypes
- Potential biomarker and therapeutic-target discoveries
- Continued development of AI-powered chemical-risk screening
- Additional biodefense and government opportunities
Lunai has also been dealing with corporate and capital-markets issues, including litigation involving alleged naked short selling. In August, the company announced that its Second Amended Complaint named six registered broker-dealers and two broker-dealer principals as defendants. Those allegations remain subject to the judicial process. A September 4 company correction stated that it changed only the reference link to the complaint and did not alter the substantive content of the earlier release.
An Increasingly Interesting AI-Biotech Convergence Story
The latest Tanaist agreement potentially adds an important missing piece to the Lunai Bioworks story.
The company already has the AI, the patient data, the proteomic analysis and the identified Parkinson's subtypes. Now it is adding another avenue for determining whether those computational discoveries correspond to real, measurable human cellular biology.
That evolution could be important.
The potential value of AI-driven drug discovery ultimately depends not simply on finding patterns, but on determining which patterns can withstand independent validation and translate into meaningful biological and therapeutic hypotheses.
Lunai is attempting to build exactly that bridge.
With Tanaist providing human cellular phenotyping, BrainStorm providing complementary experimental validation, BioSymetrics providing AI-powered patient stratification, and the company continuing its chemical-risk and biodefense work, LNAI is developing a platform that spans several rapidly advancing areas of biotechnology.
The combination of AI-driven precision medicine, human biological validation, Parkinson's disease research, biodefense and chemical-risk screening gives Lunai Bioworks $LNAI multifaceted story for investors to follow.
For more information on LNAI visit: www.lunaibioworks.com
--------------------------------------------------------------------------------------------------------------
Media Contact
Company Name: Lunai Bioworks (N A S D A Q: LNAI)
Contact: Aysha Rashid
Email: [email protected] or [email protected]
Phone: (424) 222-9301
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement | More news from this source
Press release distribution by PRLog
More News
Worldwide website emergency explained: How a critical PHP weakness sparked a global cybersecurity alert - and exactly what it means for you
A critical weakness has gone unnoticed in the very foundations of the internet for decades, but now AI has triggered a global cybersecurity alert by bringing it to light.
Read more
Cyclone Josephine forms near US East Coast as nine states are warned of storm's impact
Hurricane trackers announced that Cyclone Josephine has formed off the US East Coast. Forecasts show nine states could see storm impacts for days.
Read more
The Overlapping Plagues Quietly Devastating American Forests
Trees are suffering one devastating epidemic after another, unleashed by insects and bacteria that enter the country because of global trade.
Read more
INTERPOL Arrests 1,462 Suspects, Disrupts 10,909 Cybercrime Networks in Global Crackdown
INTERPOL on Thursday announced that a coordinated law enforcement action has disrupted 10,909 malicious networks and recovered more than $105 million in illicit funds. In tandem, the effort saw law enforcement agencies from 21 countries arrest 1,462 suspects. Codenamed Operation Serengeti III, the cybercrime crackdown took place between June 29 and August 31, 2026. "Authorities identified
Read more
Combatting online scams in the age of AI
One in four Europeans has fallen victim to an online scam, from identity fraud to fake romances. The rise of artificial intelligence is ushering in new risks. Minh Nguyen, Chief Product Officer at security solutions provider Entrust, says both online platforms and governments can play a role in protecting consumers and businesses.
Read more
Unitree developing AI system to let humanoid robots improve themselves
Unitree Robotics is developing a “self-evolving” feedback loop designed to allow humanoid robots to write code, run simulations and improve their real-world performance independently, founder Wang Xingxing said, in a move that mirrors a broader push towards “self-improving” artificial intelligence. Speaking on Thursday at a physical AI conference hosted by Unitree in Hangzhou, Wang unveiled the project, dubbed “Unitree Rehearsal”, which he called the company’s most important initiative of the...
Read more
Websites go dark worldwide after critical flaws are exposed, leaving up to 70% of sites open to attack
An urgent warning has been issued to millions after a software used by more than half of the world's websites was found to have critical flaws that could let hackers take over servers.
Read more
‘Jensen’s nightmare’: Huawei, DeepSeek narrow AI chip ecosystem gap with Nvidia: report
Deepening “symbiosis” with artificial intelligence model start-up DeepSeek is helping Chinese tech champion Huawei Technologies catch up with Nvidia’s chip hardware and software ecosystem in a scenario that could mean Jensen Huang’s “nightmare is starting to come true”, according to a new report. DeepSeek’s latest software releases, on top of its increased experimentation with Huawei’s powerful Ascend 950PR chips, reveal that the technological gap with the US is closing, as the two firms...
Read more
I.U.C.N. Red List Classifies Most Shallow Coral Reefs as Critically Endangered
If climate change continues apace, 96 percent of shallow coral reef ecosystems may collapse within 50 years, including in Australia’s Great Barrier reef.
Read more
WhatsApp, Telegram SIM binding rules from January 1, 2027: Who will be affected in India?
WhatsApp, Telegram and other messaging apps may have to remain linked to registered, active SIM cards under India's new SIM-binding rules from January 1, 2027. The DoT has set December 31, 2026, as the compliance deadline, aiming to curb cyber fraud and the misuse of Indian mobile numbers.
Read more
The AI Agent Nobody Owns: Watch Expert Webinar On Your Newest Insider Threat
Right now, there is probably an AI agent running on a laptop somewhere in your network. It stores API keys and database passwords, can access your internal systems, and works without anyone watching. Nobody reviewed its access. Nobody owns it. If an employee had that much reach with that little oversight, you would call it an insider risk. So why do we still call the agent a productivity tool?
Read moreRecommended
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.
Copyright © 2015 - 2026 The Star Journals. All Rights Reserved.